Outcomes of Functional Substrate Mapping of Ventricular Tachycardia

Launched by MID AND SOUTH ESSEX NHS FOUNDATION TRUST · Jan 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with a heart condition called ventricular tachycardia (VT), which is when the heart beats too fast and can lead to serious health issues. The goal is to see how safe and effective a specific procedure, known as functional VT ablation using the SENSE protocol, is compared to a standard treatment. Researchers will look at how many patients experience death or need additional heart device therapies within a year after the procedure.

To be eligible for the trial, participants should have had recent episodes of VT and a weakened heart function, indicated by an ejection fraction of less than 40%. Key criteria include having experienced multiple VT episodes or receiving a shock from an implantable cardioverter defibrillator (ICD) in the last six months. Participants should expect close monitoring throughout the trial, which is still recruiting, and they must meet certain health requirements to ensure their safety during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• One of the following VT events (within the last 6 months) + Ejection Fraction \<40%:
• • A: ≥3 episodes of VT treated with anti-tachycardia pacing (ATP), at least one of which is symptomatic.
• • B: ≥1 appropriate ICD shock. C: ≥3 VT episodes within 24 hr. D: Sustained VT below the detection rate of the ICD.
• Exclusion Criteria:
• • Contraindication to VT ablation
• • Renal failure (CrCl \< 15 mL/min)
• • NYHA IV or CCS IV angina
• • STEMI within 1 month
• • CABG within 3 months
• • PCI within 1 month
• • Pregnant
• • Life expectancy \< 1 year